Beneficial ownership — 13D / 13G
87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| RIVERSTONE HOLDINGS LLC | PR Permian Resources Corp | 13D/A | 6.7% | May 13, 2024 | 2y |
| Charles W. Ergen | ECHO EchoStar CORP | 13D/A | 54% | May 13, 2024 | 2y |
| Bayshore Capital LLC | WULF Terawulf Inc. | 13D/A | 6% | May 13, 2024 | 2y |
| Harraden Circle Investments, LLC | BFAC Battery Future Acquisition Corp. | 13G | 8.7% | May 10, 2024 | 2y |
| BOXER CAPITAL, LLC | ITOS iTeos Therapeutics, Inc. Common Stock | 13D/A | 8.1% | May 10, 2024 | 2y |
| Amster Howard | WHLR Wheeler Real Estate Investment Trust, Inc. | 13D/A | 16.6% | May 10, 2024 | 2y |
| Topline Capital Management, LLC | ACCS ACCESS Newswire Inc. | 13G/A | 15.9% | May 10, 2024 | 2y |
| Harraden Circle Investments, LLC | GPAT GP-Act III Acquisition Corp. | 13G | 7.5% | May 9, 2024 | 2y |
| BCM Investimentos Fundo de Investimento Multimercado Crédito Privado Investimento no Exterior | CLVR Clever Leaves Holdings Inc. Common Shares | 13D | 8.5% | May 2, 2024 | 2y |
| A.L. Sarroff Fund, LLC | PETV PetVivo Holdings, Inc. | 13G/A | 16.21% | Apr 29, 2024 | 2y |
| Christopher Savoie | ZPTA Zapata Quantum, Inc. | 13G | 5% | Mar 31, 2024 | 2y |
| Caledonia (Private) Investments Pty Ltd | LAWIL Light & Wonder, Inc. | 13G/A | 9.46% | Mar 31, 2024 | 2y |
| Lind Global Fund II LP | SNES SenesTech, Inc. | 13G/A | 9.9% | Dec 31, 2023 | 2y |
| MHR FUND MANAGEMENT LLC | TSAT Telesat Corp | 13D/A | 36.2% | May 13, 2024 | 2y |
| Michele D. Logan | GPGI GPGI, Inc. | 13D/A | 23.1% | May 13, 2024 | 2y |
| MHR FUND MANAGEMENT LLC | TWI Titan International Inc | 13D/A | 11.3% | May 13, 2024 | 2y |
| Jeffrey Wolf | SCPX Scorpius Holdings, Inc. | 13D/A | 10.5% | May 13, 2024 | 2y |
| LLR Capital IV, L.P. | GPGI GPGI, Inc. | 13D/A | 36.94% | May 13, 2024 | 2y |
| NOVO HOLDINGS A/S | IOBTQ IO Biotech, Inc. | 13G/A | 10.1% | May 10, 2024 | 2y |
| Piton Capital Partners LLC | ASYS Amtech Systems Inc | 13D/A | 19.2% | May 10, 2024 | 2y |
| Mill Road Capital III, L.P. | ALTG Alta Equipment Group Inc. | 13D/A | 9.8% | May 10, 2024 | 2y |
| Artal International S.C.A. | LXRX Lexicon Pharmaceuticals, Inc. | 13D/A | 48.4% | May 10, 2024 | 2y |
| FINDELL CAPITAL MANAGEMENT LLC | OPRT Oportun Financial Corp | 13D/A | 9.7% | May 10, 2024 | 2y |
| Ernest C. Garcia II | CVNA Carvana Co. | 13D/A | 42.2% | May 10, 2024 | 2y |
| Mitchell P. Kopin | HSDT Solana Co | 13G | 4.99% | May 9, 2024 | 2y |
| MILLENNIUM MANAGEMENT LLC | MRVI Maravai Lifesciences Holdings, Inc. | 13G | 5.4% | May 9, 2024 | 2y |
| Jason Gardner | MQ Marqeta, Inc. | 13G/A | 10.7% | May 6, 2024 | 2y |
| Ezra Dabah | PIK Kidpik Corp. Common Stock | 13D/A | 65.3% | Mar 29, 2024 | 2y |
| Aleksander Migon | BASE Couchbase, Inc. Common Stock | 13G/A | 6.4% | Mar 8, 2024 | 2y |
| Cove Street Capital, LLC | RSSS Research Solutions, Inc. | 13D/A | 8.64% | May 13, 2024 | 2y |
| BAKER BROS. ADVISORS LP | INCY Incyte Corp | 13D/A | 16.3% | May 12, 2024 | 2y |
| Stanley Kesselman | CVR Chicago Rivet & Machine Co | 13G | 5% | May 10, 2024 | 2y |
| Hill Path Capital LP | PRKS United Parks & Resorts Inc. | 13D/A | 43.6% | May 9, 2024 | 2y |
| Patel Tushar Bhikhubhai | AMRX Amneal Pharmaceuticals, Inc. | 13D/A | 17.4% | May 9, 2024 | 2y |
| New Enterprise Associates 16, L.P. | BDTX Black Diamond Therapeutics, Inc. | 13D/A | 8.1% | May 9, 2024 | 2y |
| Madryn Asset Management, LP | GBNH Greenbrook TMS Inc. Common Shares | 13D/A | 61.2% | May 9, 2024 | 2y |
| New Enterprise Associates 17, L.P. | GLUE Monte Rosa Therapeutics, Inc. | 13D/A | 15.4% | May 9, 2024 | 2y |
| Nathan D. Hukill | TTOO T2 Biosystems, Inc | 13D/A | 69.5% | May 9, 2024 | 2y |
| Hoak Public Equities, LP | WHG Westwood Holdings Group Inc | 13D/A | 7.8% | May 9, 2024 | 2y |
| The Westaim Corporation | SKWD Skyward Specialty Insurance Group, Inc. | 13G/A | 4.8% | May 9, 2024 | 2y |
| Saba Capital Management, L.P. | ECF Ellsworth Growth & Income Fund Ltd | 13D | 5.32% | May 8, 2024 | 2y |
| SUVRETTA CAPITAL MANAGEMENT, LLC | ABEO Abeona Therapeutics Inc. | 13G | 9.3% | May 3, 2024 | 2y |
| Cormorant Asset Management, LP | CTMX CytomX Therapeutics, Inc. | 13G | 7.38% | May 2, 2024 | 2y |
| Avidity Partners Management LP | CNTX Context Therapeutics Inc. | 13G | 9.9% | May 2, 2024 | 2y |
| MMCAP International Inc. SPC | CCIX Churchill Capital Corp IX | 13G | 6.1% | May 2, 2024 | 2y |
| S.H.N. Financial Investments Ltd. | CETX Cemtrex Inc | 13G | 9.99% | May 1, 2024 | 2y |
| Allostery Investments LP | AVTX Avalo Therapeutics, Inc. | 13G | 7.6% | May 1, 2024 | 2y |
| SAMLYN CAPITAL, LLC | CRVS Corvus Pharmaceuticals, Inc. | 13G/A | 9.99% | May 1, 2024 | 2y |
| Anette Schmid | SHMD SCHMID Group N.V. | 13D | 30.3% | Apr 30, 2024 | 2y |
| PERCEPTIVE ADVISORS LLC | BDSX Biodesix Inc | 13G | 5.6% | Apr 9, 2024 | 2y |